Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

End-of-day quote. End-of-day quote  - 07/26
3304.75 INR   -5.28%
07/26 DR REDDY LABORA : . Reddy’s Q1 FY17 Financial Results
07/26 DR REDDY LABORA : Doctor Reddy's posts 1Q profit
07/26 DR REDDY LABORA : . Reddy’s Q1 FY17 Financial Results
News SummaryMost relevantAll newsSector news 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
07/26 DR REDDY LABORATORIES : . Reddy’s Q1 FY17 Financial Results
07/26 DR REDDY LABORATORIES : Doctor Reddy's posts 1Q profit
07/26 DR REDDY LABORATORIES : . Reddy’s Q1 FY17 Financial Results
07/19 DR REDDY LABORATORIES : Drl launches heartburn drug
07/18 DR REDDY LABORATORIES : Creation of branded generics platform in the US expected..
07/18 DR REDDY LABORATORIES : Announces the Launch of Omeprazole and Sodium bicarbonat..
07/18 DR. REDDY'S LABORATORIES LIMITED : ex-dividend day for annual dividend
07/14 DR REDDY LABORATORIES : Recalls over 9,000 bottles anti-organ rejection drug in ..
07/12DJTeva Raises Guidance
07/12 DR REDDY LABORATORIES : . Reddy's to Release Q1 FY17 Results on July 26, 2016  E..
More news
Sector news : Pharmaceuticals - NEC
08:55aDJBAYER : Second-Quarter Profit Rises
08:37aDJBAYER : Second-Quarter Profit Rises 18.6%
08:35aDJBAYER : Second-Quarter Profit Rises 18.6%
07/26 Exclusive - Teva, Mylan eye Pfizer's Brazil venture, sources say
07/26DJEli Lilly Revenue Rise Helped by New Products
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12:15a Dr. Reddy's Laboratories' (RDY) Q2 2016 Results - Earnings Call Transcript
07/26 Midday Gainers / Losers
07/26 Dr.Reddy's Laboratories revenues off 14% in FQ1
07/26 Dr. Reddy's reports FQ1 results
Financials ( INR)
Sales 2017 160 982 M
EBIT 2017 27 422 M
Net income 2017 22 726 M
Finance 2017 6 842 M
Yield 2017 0,62%
P/E ratio 2017 25,56
P/E ratio 2018 20,23
EV / Sales 2017 3,47x
EV / Sales 2018 2,97x
Capitalization 566 134 M
More Financials
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 44
Average target price 3 393  INR
Spread / Average Target 2,2%
Consensus details
EPS Revisions
More Estimates Revisions
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.84%344 243
PFIZER INC.14.10%223 368
NOVARTIS AG-5.30%219 971
ROCHE HOLDING LTD.-9.99%218 902
MERCK & CO., INC.10.49%161 542
More Results